Tesamorelin: Egrifta Versus Research-Grade Material

Egrifta and research-grade tesamorelin contain the same 44-amino-acid peptide, and almost nothing else about them is the same. Egrifta is a licensed biologic, manufactured and released under drug controls, formulated with specific excipients and labeled for one indication in adults with HIV. Research-grade tesamorelin is a laboratory reagent whose only specification is the certificate issued for each lot. The molecule can be identical while the product, the evidence behind it and the permitted use are entirely different.

What exactly is tesamorelin?

Tesamorelin is a synthetic analog of human growth hormone-releasing factor: the full 44-amino-acid sequence with a hexenoyl group, a six-carbon chain carrying a double bond at position 3, attached to the N-terminal tyrosine. The approved product is the acetate salt, with molecular formula C221H366N72O67S and a molecular weight of 5,135.9 Da expressed as the free base (EGRIFTA WR prescribing information). The N-terminal modification protects the peptide from rapid enzymatic cleavage, which is what lets a once-daily injection sustain growth hormone release.

The approved indication is narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label adds limitations of use that matter for anyone reading the research literature. Long-term cardiovascular safety has not been established, the product is not indicated for weight loss, and there are no data showing improved adherence to antiretroviral therapy. It is contraindicated with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity and pregnancy.

How do Egrifta and research-grade tesamorelin differ?

Point by point, the differences sit in everything around the peptide.

Attribute	Egrifta (approved product)	Research-grade tesamorelin
Legal status	Licensed biologic, BLA 022505; approved as a drug in 2010, deemed a biologics license on March 23, 2020	Laboratory reagent, research use only; no license
Indication	Excess abdominal fat in HIV-infected adults with lipodystrophy	None
Formulation	Sterile lyophilized powder with mannitol (original) or hydroxypropyl betadex and mannitol (current)	Peptide salt, usually without excipients; sterility not implied
Strength	1 mg, 2 mg or 11.6 mg per vial, by formulation	Labeled solid mass, set by the supplier
Dose	2 mg, 1.4 mg or 1.28 mg daily, by formulation; not interchangeable	Not applicable; not for human use
Lot release	Against a registered specification under drug manufacturing controls	Against the supplier’s certificate of analysis
Evidence base	Two phase 3 trials, 740 patients, plus extensions	Borrowed from the approved product’s trials; none of its own

Table 1: Egrifta compared with research-grade tesamorelin, from the EGRIFTA WR and 2010 EGRIFTA prescribing information and the FDA list of NDAs transitioned to biologics licenses in 2020.

The formulation row is the one most often overlooked. The original product contained 1 mg of tesamorelin free base (1.1 mg of the acetate) with 50 mg of mannitol per vial and had to be refrigerated (EGRIFTA 2010 prescribing information); the current version adds hydroxypropyl betadex and is stored at room temperature. Excipients change stability, solubility and dose, which is why the label states the formulations are not substitutable. A research vial matches none of them, so the approved product’s data describe it only at the level of the molecule.

The licensing row matters for a different reason. Synthetic peptides of more than 40 amino acids approved as drugs were moved to biologics licenses in 2020, and tesamorelin was one of them. Why a compound can sit on an approved-drug list and a research catalog at the same time, and why lists of approved peptides disagree, is covered in why approved peptide lists differ.

What did the trials behind the approval show?

The pivotal evidence is a body-composition result in a defined population. In a 26-week randomized trial, 412 patients with HIV and abdominal fat accumulation, 86% of them men, received 2 mg of tesamorelin or placebo daily. Visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo; triglycerides fell 50 mg/dL against a 9 mg/dL rise, and IGF-I rose 81.0% against a 5.0% fall, with P<0.001 for each comparison (Falutz et al., N Engl J Med 2007). Glycemic measures did not differ significantly, though more patients on tesamorelin withdrew because of an adverse event.

Two qualifications belong beside those numbers. The effect depends on continued treatment: reductions held to week 52 in the extension phases, while stopping was followed by reaccumulation (Dhillon, BioDrugs 2011). And the response did not depend on a visible fat pad: a post hoc analysis of the phase 3 data found visceral fat and waist reductions did not differ between people with and without dorsocervical fat (P = 0.657 and P = 0.093) (Rahman et al., J Clin Transl Sci 2023).

Pharmacokinetics explain why the formulation cannot be improvised. The original label reports absolute bioavailability of less than 4% after a 2 mg subcutaneous dose in healthy adults (EGRIFTA 2010 prescribing information). With so little of the injected peptide reaching the circulation intact, small differences in formulation or peptide content change exposure disproportionately, one reason the reformulated products carry different doses. The wider barriers to peptide absorption are covered in peptide oral bioavailability barriers.

What should a research-grade certificate show for this molecule?

Two measurements tied to the vial’s batch number, plus two details specific to tesamorelin.

Identity by mass spectrometry. The observed mass should match 5,135.9 Da for the free base, or the salt form stated. A 44-residue chain has many positions where a synthesis can drop a residue, and those deletion products sit close to the target in mass and structure.

Purity by HPLC. Area percent of the dominant species. Purity without identity says one species dominates, not which one.

Oxidation. The single sulfur atom in the formula belongs to a methionine residue, a common oxidation site. The oxidized form weighs 16 Da more and is visible on the mass spectrum; its level is a direct readout of handling and storage.

Net peptide content. The approved label itself reports vial content two ways, 1 mg of free base as 1.1 mg of acetate, which is the same distinction net peptide content captures. Without it, labeled milligrams are an upper bound on peptide.

Suppliers publish different subsets of these. HEEZ Research, for example, states that each tesamorelin lot carries a batch-specific third-party certificate covering HPLC purity and MS identity; oxidation and net peptide content are the fields to look for beyond that. How the same documentation affects the cost of usable material is worked through in what determines tesamorelin cost.

Does research-grade tesamorelin have a legitimate use?

Yes, as a reagent: receptor binding and signaling assays, analytical method development, stability work and animal studies under institutional approval. It is supplied to qualified organizations for laboratory research only and is not for human consumption. None of that makes it an alternative to the licensed product for a patient, because it has no license, no sterility specification and no labeled dose.

Clinical questions stay with the licensed product. A double-blind trial registered as NCT06554717 is testing 24 weeks of tesamorelin or placebo with a home-based exercise program in 100 adults with HIV aged 50 to 80, followed by a 24-week extension; it has published a protocol and no results (Erlandson et al., BMJ Open 2026).

Common questions about Egrifta and research-grade tesamorelin

Is research-grade tesamorelin the same as Egrifta? The peptide sequence is the same; the product is not. Egrifta is a licensed, formulated, sterile biologic with a labeled dose. Research-grade tesamorelin is a documented reagent.

Why are there three Egrifta doses? Each formulation was approved to deliver equivalent treatment at its own labeled dose: 2 mg for the original, 1.4 mg for Egrifta SV and 1.28 mg for Egrifta WR. They are not interchangeable.

Is tesamorelin a biologic or a drug? A biologic. It was approved as a drug in 2010 and deemed a biologics license on March 23, 2020, when synthetic peptides above 40 amino acids moved to that pathway.

Is tesamorelin approved for weight loss? No. The label states it is not indicated for weight loss.